Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center discusses COVID 19 and how it...
Welcome Home Sidebar Block
VIDEOS
In partnership with Clinical Care Options, GRACE Founder and President H. Jack West, MD provides this informational video regarding immunotherapy for...
Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center interviews Julia Maues, breast...
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of...
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate...
ARTICLES
Yesterday, news that the Checkmate 026 trial that compared the PD1 checkpoint inhibitor Opdivo (nivolumab) to standard chemotherapy as first line...
The transition of PD1 and PD-L1 inhibitors into the first line setting for at least some patients with advanced non-small cell lung cancer (NSCLC) is...
The medical community has made significant progress in understanding that lung cancer is not a single cancer, and are treating it accordingly. We’ve...
Probably the most immediate potentially practice-changing presentation from ASCO was the Japanese J-ALEX study in the subset of about 4-5% of patients...
It seemed inevitable, I think. Several immuntherapy agents known as PD-1 or PD-L1 checkpoint inhibitors have been shown to lead to better survival...
COMMUNITY FORUM
Hi, My mother is currently on Alimta infusions ( 4th dosage), Her primary side effect since the start was severe nerve pain, which was under control...
I am new here looking for advice if this is a right place. Annual CT scans have identified a stable right upper lobe Ground Glass Nodule (GGN)...
My wife is taking treatment for EGFR mutant lung cancer that had spread to her brain. She started with tagrisso and later after resistant went thru...
Hi, my sister (47 YO, Seattle, WA) was diagnosed with lung cancer (non small cell adenocarcinoma) spring 2019. She had symptoms for a year before that...
The ADAURA clinic trial has proven that patients taking Tagrisso with IB-IIIA NSCLC had a 79% reduction in disease recurrence and the disease free...